Reply to L. Marandino et al

Abstract

We had the opportunity to discuss the measurement of quality-of-life (QOL) outcomes in prostate cancer clinical trials in the context of the recently published study by Stockler et al 1 in which they characterized the QOL outcomes from ENZAMET, an international phase III trial of enzalutamide versus active control (physician's choice of bicalutamide, nilutamide, or flutamide) in combination with androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer. 2 In response to this publication, Marandino et al 3 raised important points regarding the importance of cognitive function as a crucial QOL outcome requiring accurate and uniform measurement in patients with prostate cancer receiving novel hormonal therapy (NHT) such as enzalutamide in combination with ADT.